NantOmics
| Company type | Limited liability |
|---|---|
| Industry | Biotechnology, molecular diagnostics |
| Founded | 2013 |
| Founder | Patrick Soon-Shiong |
| Headquarters | , |
| Products | Molecular diagnostic products |
NantOmics is a biotechnology company based in Culver City, California, which provides molecular diagnostic products for personalized cancer treatment. It is part of the NantWorks network, a corporation consisting of different startups in the medical and health industry.[1]
History
NantOmics was founded in 2013 by billionaire Patrick Soon-Shiong. In 2015 NantOmics bought the cancer diagnostics company OncoPlex Dx.[2] In 2017 the company acquired the consumer genomics startup Genos.[3]
In 2016 the company's revenue was about $58.3 million with a net loss of about $72.00 million.[4] As of 2017, the company is classified as a unicorn startup with an estimated value of over $1 billion.[5][6]
Products
GPS Cancer involves sequencing of the genome and RNA of tumor cells in comparison to normal cells from the same individual in order to develop personalized treatments.[7] About 327,000 cancer patients participated in a GPS cancer pilot project in 2017.[8]
References
- ^ "NantOmics, LLC: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2018-03-30.
- ^ "NantOmics Acquires OncoPlex Diagnostics, an Accredited Proteomics Diagnostic Laboratory". Retrieved 2018-03-30.
- ^ "Bio-IT World". www.bio-itworld.com. Retrieved 2018-03-30.
- ^ "NantHealth files for $92 million IPO". MobiHealthNews. 2016-05-09. Retrieved 2018-03-30.
- ^ "The unicorns of SoCal Tech: 15 startups valued at more than $1B". Built In Los Angeles. Retrieved 2019-04-23.
- ^ "Unicorn startups: Billion-dollar startups (2018 updated list)". Startups News | Tech News. 2018-04-08. Retrieved 2019-04-23.
- ^ "GPS Cancer Overview". GPS Cancer. Retrieved 2018-03-30.
- ^ "NantHealth Reports 16% Increase in 2017 First Quarter Total Net Revenue; SaaS Revenue Rose 11% and GPS Adoption Continues to Climb". Retrieved 2018-03-30.